Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAYTULLA vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 14 years old who have achieved menarche and are using contraception (off-label),Treatment of premenstrual dysphoric disorder (PMDD) in women who desire oral contraception (off-label)
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One capsule orally once daily for 24 weeks.
400 mg orally once daily with food.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Ethinyl estradiol: CYP3A4, sulfation, glucuronidation. Drospirenone: CYP3A4, reduction, sulfation, glucuronidation.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
>=90% bound to albumin and alpha-1-acid glycoprotein.
98% bound to albumin
3.5 L/kg, indicating extensive tissue distribution.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: 87% (immediate-release); TAYTULLA formulation: 79% relative to immediate-release.
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (Cr Cl <30 m L/min); use with caution.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in patients with Child-Pugh Class B or C hepatic impairment. Use with caution in Child-Pugh Class A.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not approved for use in pediatric patients.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects; use with caution due to potential for decreased hepatic, renal, or cardiac function.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Thrombotic disorders (DVT, PE, stroke, MI), hypertension, gallbladder disease, hepatic neoplasia, hyperkalemia (especially in patients with renal/hepatic impairment or on potassium-sparing drugs), depression, impaired glucose tolerance, weight gain, fluid retention, irritability, mood changes.
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast cancer, endometrial carcinoma or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenoma or carcinoma, known or suspected pregnancy, hypersensitivity to any component, uncontrolled hypertension, diabetes with vascular involvement, headaches with focal neurological symptoms, major surgery with prolonged immobilization, heavy smoking and age >35 years.
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No specific food interactions are known. Grapefruit juice may theoretically increase estrogen levels due to CYP3A4 inhibition, but clinical significance is unclear. Avoid excessive alcohol consumption as it may impair liver function and increase VTE risk.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
TAYTULLA (drospirenone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from inadvertent use, but postmarketing studies show a small increased risk of non-cardiac malformations. Second and third trimesters: Associated with fetal harm including cardiovascular and skeletal malformations, and feminization of male fetuses due to estrogenic effects.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Drospirenone and ethinyl estradiol are excreted in human milk in small amounts (M/P ratio not established). Use during lactation is not recommended as it may reduce milk production and composition. Alternative contraception should be considered.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
TAYTULLA is contraindicated in pregnancy; no dose adjustments are applicable as use should be discontinued immediately upon pregnancy detection. No pharmacokinetic studies in pregnancy are available.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
TAYTULLA is a combined hormonal contraceptive containing estetrol (E4) and drospirenone. It is the first contraceptive to use estetrol, a native estrogen with selective tissue activity. Its unique pharmacokinetics allow for a 24/4 regimen with a 4-day hormone-free interval. The progestin drospirenone has antimineralocorticoid activity, which can help reduce water retention and may be beneficial in patients with acne or premenstrual dysphoric disorder. Due to the risk of hyperkalemia, monitor serum potassium in patients on concomitant medications that increase potassium levels, such as ACE inhibitors, ARBs, NSAIDs, or potassium-sparing diuretics. The risk of venous thromboembolism (VTE) is present, and patients should be counseled on symptoms. TAYTULLA is contraindicated in patients with a BMI ≥ 35 kg/m² due to increased VTE risk.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one tablet daily at the same time, preferably after the evening meal. The pill pack contains 24 active tablets (white) followed by 4 placebo tablets (yellow).,If you miss a white tablet, take it as soon as you remember, even if it means taking two tablets in one day. If you miss a white tablet for more than one day, use backup contraception for the next 7 days.,This medication does not protect against HIV or other sexually transmitted infections. Use condoms for STI protection.,Common side effects include headache, nausea, breast tenderness, and mood changes. Contact your healthcare provider if you experience severe abdominal pain, chest pain, shortness of breath, or leg pain/swelling, which may indicate a blood clot.,Smoking increases the risk of serious cardiovascular side effects. Women over 35 who smoke should not use this medication.,Inform your healthcare provider of all medications you take, especially those that affect potassium levels (e.g., certain blood pressure medications, NSAIDs, potassium supplements).
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAYTULLA vs ADQUEY, answered by our medical review team.
TAYTULLA is a Oral Contraceptive that works by Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAYTULLA and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAYTULLA is: One capsule orally once daily for 24 weeks.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TAYTULLA and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TAYTULLA is classified as Category C. TAYTULLA (drospirenone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from inadvertent use, but postmarketing studies. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.